Newsroom

RSS feed

Media Enquiries

Sharon McHale
Sharon McHale
Head of Public Affairs
CSL Limited
Mobile: +61 409 978 314
Email: sharon.mchale@csl.com.au
45 Poplar Rd, Parkville
Victoria 3052 Australia

25/04/2016
CSL Celebrates 100 Years of Operation
Australia’s largest and most successful biotechnology company, CSL, will officially celebrate 100 years of operation on 25th April 2016. More.

14/04/2016
CSL Announces $25 million Centenary Fellowship Program
CSL is proud to announce the establishment of a new flagship $25 million fellowship program for early stage and translational research in Australia. More.

07/03/2016
Expanded Bio21 to house global research hub
The University of Melbourne’s internationally recognized Bio21 Molecular Science and Biotechnology Institute is to be substantially expanded and will house CSL’s Global Research and Translational Medicine Hub. More.

07/03/2016
IDELVION® (rFIX-FP) – FDA approval
CSL today announced that the U.S. Food and Drug Administration (FDA) has approved IDELVION [Coagulation Factor IX (Recombinant), Albumin Fusion Protein], CSL Behring’s novel, long-acting albumin fusion protein linking recombinant coagulation factor IX with recombinant albumin for the treatment of haemophilia B. More.

29/02/2016
IDELVION® (rFIX-FP) - CHMP recommendation
CSL today announced that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended granting marketing authorization for IDELVION® (Coagulation Factor IX (Recombinant), Albumin Fusion Protein) for patients with haemophilia B. More.

16/02/2016
CSL Appoints New Director
CSL Limited (ASX:CSL; USOTC:CSLLY) - CSL today announced that Dr Megan Clark AC has been appointed as a Director of the Company effective from 16 February 2016. More.

16/02/2016
Half Year Result 2016
CSL Delivers Exceptional Performance

CSL Limited (ASX:CSL; USOTC:CSLLY) today announced a net profit after tax (NPAT) of US$719 million for the six months ended 31 December 2015, up US$27 million or 4% on a reported basis when compared to the prior comparable period (PCP). Earnings per share (EPS) grew 6%. After excluding financials relating to the recently acquired Novartis influenza vaccines business, underlying1 NPAT grew 7% and EPS grew 9%, at constant currency2. More.

10/12/2015
Research & Development Investor Briefing
CSL Limited (ASX:CSL; USOTC:CSLLY) conducted its annual research & development briefing for investors on Thursday 10 December 2015. More.

27/11/2015
CSL Salutes the Australian Science Media Centre
CSL congratulates the Australian Media Science Centre (AusSMC) on ten years of service to the Australian community. More.

09/11/2015
CSL brands world’s no. 2 influenza vaccine provider as Seqirus
Global biotherapeutics leader CSL Limited announced that its influenza vaccines business will begin operating under the brand Seqirus effective today, following the merger of the recently-acquired Novartis influenza business and its existing vaccines and pharmaceutical business bioCSL. More.

15/10/2015
CSL Welcomes New Lifetime Immunisation Register
CSL congratulates the Federal Government on the successful passage of legislation to establish an Australian Immunisation Register (AIR). The new register, which will be progressively introduced, will capture all vaccines that Australians receive from birth to death. More.

15/10/2015
CSL announces record A$1 billion share buyback
CSL today announced a new on-market share buyback of up to A$1 billion. The new buyback will be the largest ever undertaken by the company as part of its regular buyback program. More.

09/10/2015
CSL Names David Lamont as Chief Financial Officer
CSL today named Mr. David Lamont, an accomplished global financial leader with a diverse commercial background, as its Chief Financial Officer (CFO), effective 2 January 2016. He will be based at CSL’s headquarters in Parkville, Australia. As announced in August, CSL CFO Mr. Gordon Naylor is transitioning to the role of President of Seqirus, the new global business created from the integration of bioCSL and the newly acquired Novartis influenza vaccines business. More.

09/10/2015
New CHF400 Million & USD100 Million US Private Placement
CSL today announced that on 8 October 2015 it has closed a new CHF400 million and USD100 million private placement in the US. The private placement was foreshadowed in CSL’s full year results announcement in August 2015 More.

07/09/2015
CSL standing firm on Enterprise Agreement Offer
Union demands for a pay rise of 11.5% over 3 years are not sustainable says CSL as it prepares to put its offer of a 9.75% wage increase to an employee vote for the second time. Unions are instructing employees to hold out for more while ongoing industrial action starts to impact the export of haemophilia products into Europe. More.

12/08/2015
Strong Full Year Result
CSL Limited (ASX:CSL; USOTC:CSLLY) today announced a net profit after tax (NPAT) of US$1,379 million for the full year ended 30 June 2015, up 6% on a reported basis when compared to the prior comparable period (PCP). NPAT grew 10% on a constant currency1 basis, after adjusting for the one-off costs2 associated with the acquisition of the Novartis influenza vaccine business. More.

04/08/2015
CSL Supports New Medical Research Future Fund
Melbourne, Australia – CSL told the Senate Inquiry into the Medical Research Future Fund (MRFF) in Melbourne today that it was strongly supportive of the new fund and saw it as an acknowledgement of the significant economic benefits that Australia derives from investment in medical research. More.

03/08/2015
Australia’s Innovation System Could Deliver More
Australia’s System of Innovation has the potential to deliver significantly more in terms of economic productivity, CSL told a Senate Inquiry in Melbourne today. More.

03/08/2015
CSL completes Novartis influenza vaccine business acquisition
CSL Limited (ASX:CSL; USOTC: CSLLY) today announced that it has now closed its transaction to acquire Novartis global influenza vaccine business for a cash consideration of US$275 million. More.

31/07/2015
Update on Novartis influenza vaccines acquisition
CSL Limited (ASX:CSL; USOTC: CSLLY) today announced that it has secured the necessary approvals required to proceed with the acquisition of the influenza vaccines business of Novartis and that it is working with Novartis to bring forward the close date for the transaction. The Company also said the new CSL subsidiary resulting from the acquisition will be called Seqirus. More.

28/07/2015
Competitive Advanced Manufacturing - Quite within Reach for Australia
Securing a globally competitive locally-based advanced manufacturing sector is quite within reach for Australia, according to CSL Limited, Australia’s largest biotechnology company. The key is to make a serious, strategic effort to attract footloose global investment, especially targeting innovations and ideas developed in Australia. More.

28/07/2015
U.S. FDA Accepts for Review CSL Behring’s BLA for its Novel rVIII-SingleChain Therapy for Patients with Haemophilia A
CSL Limited (ASX:CSL; USOTC: CSLLY) announced today that the U.S. Food and Drug Administration (FDA) has accepted for review CSL Behring’s Biologics License Application (BLA) for its novel investigational recombinant factor VIII single-chain (rVIIISingleChain) for the treatment of haemophilia A. In the pivotal clinical trial, rVIIISingleChain met all primary endpoints. More.

18/06/2015
CSL Aquires Exclusive Rights to Influenza Treatment
CSL Limited (ASX:CSL) today announced it has acquired exclusive rights to commercialise the influenza treatment, RAPIVAB®, from US-based company, BioCryst Pharmaceuticals Inc (NASDAQ: BCRX). More.

17/06/2015
CSL Behring to Present Pivotal Data for rVIII-SingleChain and rIX-FP at
ISTH Congress

CSL Limited (ASX:CSL; USOTC:CSLLY) today announced that CSL Behring will present more than 20 abstracts, including five oral presentations, from across its hematology portfolio of investigational and branded products at the 2015 International Society on Thrombosis and Haemostasis (ISTH) Congress being held in Toronto June 20 through 25. The presentations will include pivotal trial data for two of its late-stage recombinant products – its novel recombinant factor VIII SingleChain (rVIII-SingleChain) compound for hemophilia A and its long-acting recombinant factor IX albumin fusion protein (rIX-FP) for hemophilia B. More.

15/06/2015
Tax Competitiveness for Advanced Manufacturing the key to commercialising Australian R&D
A more competitive corporate tax rate would enable Australia to attract valuable investment in advanced manufacturing and in turn convert its world leading R&D into fully-fledged industries located in Australia, according to CSL Limited, Australia’s largest biotechnology company. More.

23/04/2015
Gordon Naylor to lead CSL’s Global Influenza Vaccine Business
CSL Limited (ASX:CSL; USOTC:CSLLY) – CSL today announced that Gordon Naylor will lead CSL’s new global influenza vaccine business, which is planned for launch at the start of 2016. Mr Naylor is currently the Company’s Chief Financial Officer and has held executive management responsibility for CSL’s existing vaccines and pharmaceutical subsidiary, bioCSL, since 2012. More.

30/03/2015
European Medicines Agency Commences Review of CSL Behring's Regulatory Submission for rIX-FP for Hemophilia B Patients
CSL Behring announced today that the European Medicines Agency (EMA) has started the Centralized Procedure for reviewing the company's Marketing Authorization Application (MAA) for its long-acting fusion protein linking recombinant coagulation factor IX with recombinant albumin (rIX-FP). More.

11/02/2015
Half Year Result 2015
CSL Limited (ASX:CSL; USOTC:CSLLY) today announced a net profit after tax (NPAT) of US$692 million for the six months ended 31 December 2014, up US$47 million or 7% on a reported basis when compared to the prior comparable period (PCP). Earnings per share (EPS) grew 10%. More.

04/12/2014
CSL Welcomes China Entrepreneur Club Delegation
CSL Limited (ASX:CSL) today welcomed a delegation from the China Entrepreneur Club (CEC), the premier business leader platform in China, to their Broadmeadows site in Melbourne. The visit provided an opportunity to share knowledge, experiences and explore collaborative opportunities. More.

>> Prior Archived Newsroom


 

Media Enquiries - CSL Limited
Sharon McHale
Senior Director Public Affairs
Phone: +613 9389 3425
Mobile: +61 409 978 314
Email: sharon.mchale@csl.com.au
45 Poplar Rd, Parkville
Victoria 3052
Australia

© 2016 CSL Limited